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ABSTRACT
Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib 
acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular 
endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor 
receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.
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INTRODUCTION
Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of 
hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. 
Cutaneous adverse reactions are common with sorafenib but acneiform 
eruptions are very rare, although it has a widely-reported association 
with epidermal growth factor receptor (EGFR) inhibition and EGFR 
inhibitors with incidence between 20% to 90% [1,2].
CASE REPORT
Informed consent was taken from the patient for this case report. 
A 21-year-old male, known case of cirrhosis of liver, hepatocellular 
carcinoma who had underwent left lobe of liver resection was admitted 
with complaints of abdominal pain. On examination, vitals were stable, 
systemic examination was normal and laboratory investigations were 
normal. Ultrasound abdomen revealed altered echotexture in right 
lobe of liver with thrombosis in main pancreatic duct causing partial 
obstruction. The patient was conservatively managed with antibiotics 
and fluids. He was also started on sorafenib 200 mg twice daily, and 
after starting the medication by 3rd day, he developed rashes all over 
his body and pimples on his back. On examination skin, colored papules 
were seen over chest, face, and scalp, and back. Scaling was also noted in 
scalp. A diagnosis of sorafenib induced acneiform eruptions was made. 
The patient was started with isotretinoin with clindamycin cream to be 
topically applied 1 hr once in a day for 2 weeks. Furthermore, Salisia 
KT shampoo was given for scalp lesions for 2 weeks. Sorafenib was 
continued at the same dosage. Patient improved on discharge.
DISCUSSION
Sorafenib, a bi-aryl urea class of drug with a molecular weight of 
630 ug/mol [3] acts by inhibiting various kinases such as tyrosine 
kinase, rearranged during transfection tyrosine kinase, EGFR, 
vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and 
cell proliferation [1]. In contrast to EGFR inhibitors, cutaneous drug 
reactions are less with sorafenib. Some of the common cutaneous 
toxicities of sorafenib are listed in Table 1. Acneiform eruptions 
are known side effect of EGFR inhibitors with an incidence ranging 
between 20% and 90% [4], but acneiform eruptions with sorafenib 
is seldom seen with only 5 definite cases reported so far in literature 
with a median time of 4 weeks for development of lesions [5-7]. Usually, 
it is mistaken for acute generalized exanthematous pustulosis but 
that is more common with antiepileptic group of drugs [8]. Normal 
epidermal growth process depends on the presence of EGFR present 
in follicular and epidermal keratinocytes. Tyrosine kinase receptor is 
attached to the intracellular domain of EGFR. This is responsible for 
phosphorylation of downstream signaling proteins, and one of them is 
the Raf/MEK/ERK pathway which is involved in cell cycle progression 
and proliferation. Sorafenib inhibits tyrosine kinase thereby preventing 
phosphorylation and hence forth modifying the action of Raf/MEK/
ERK pathway. This is mainly responsible for skin reactions associated 
with sorafenib. Treatment depends mainly on severity of lesions. Since 
acneiform eruptions responds well to oral as well as local therapy, 
there is no dose limitation or need for stopping sorafenib. Preventive 
measures are not well developed, yet preventive treatment with oral 
fusidic acid or topical 4% erythromycin emulsion has been satisfactory 
in reducing the occurrence of pustules. Intranasal mupirocin is usually 
used to avoid secondary bacterial infections [7].
In our case patient developed acute acneiform eruptions within 4 days 
of starting treatment with sorafenib and other medications causing 
acne was ruled out. Causality assessment, severity, and preventability 
assessment were done as per Naranjo’s, Hartwig’s, and Thornton’s 
scaling [9], respectively (Table 2). A probable causal relationship was 
established, and hence sorafenib was confirmed to be the culprit.
CONCLUSION
Sorafenib now being a potential new drug in the treatment of solid 
tumors and skin related toxicities like acneiform eruptions being 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16805
Case Report
Table 1: Cutaneous adverse reactions associated with sorafenib
Alopecia
Hand-foot skin reaction
Erythematous eruption on trunk
“Rash”/desquamation





Epidermal cyst on face
Erythema marginatum hemorrhagicum
Genital (labial and scrotal) eczema
Eruptive melanocytic nevi
Leukocytoclastic vasculitis
Nonpigmented fixed drug eruption
Perforating folliculitis
Spiny follicular hyperkeratosis eruption
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very rare when compared to EGRF inhibitors and in comparison, to 
other cutaneous reactions due to sorafenib. Hence, proper preventive 
measures can be advised to avoid extensive lesions with papules. 
Further prospective studies can be done to find out whether dose 
reduction or discontinuation of sorafenib has better outcomes in the 
management of acneiform eruptions.
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Table 2: Adverse drug reaction assessment
Naranjo’s scale Probable
Hartwig’s scale Mild severity
Thorntons’s scale Not preventable
